Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Burney Co.

Burney Co. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,623 shares of the biopharmaceutical company’s stock after selling 709 shares during the quarter. Burney Co.’s holdings in Gilead Sciences were worth $612,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. nVerses Capital LLC acquired a new position in Gilead Sciences during the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the period. Cedar Wealth Management LLC lifted its position in shares of Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences in the second quarter valued at $33,000. Finally, Quarry LP purchased a new stake in Gilead Sciences during the 2nd quarter worth $43,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on GILD shares. Oppenheimer upped their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Mizuho raised their price objective on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. BMO Capital Markets upped their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Citigroup assumed coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target for the company. Finally, Wells Fargo & Company upped their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $97.96.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock worth $42,130,461 in the last 90 days. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Trading Up 0.2 %

Gilead Sciences stock opened at $91.84 on Friday. The firm has a 50-day moving average price of $91.85 and a two-hundred day moving average price of $83.81. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The firm has a market capitalization of $114.46 billion, a price-to-earnings ratio of 1,020.44, a PEG ratio of 1.27 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.29 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.35%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s payout ratio is currently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.